Isoflavone supplementation in postmenopausal women does not affect leukocyte LDL receptor and scavenger receptor CD36 expression: A double‐blind, randomized, placebo‐controlled trial

Engelbert, Ann Katrin; Soukup, Sebastian T.; Röth, Alexander; Hoffmann, Nadine; Gräf, Daniela; Watzl, Bernhard; Kulling, Sabine E.; Bub, Achim

doi:10.1002/mnfr.201600019

Cited by 9 publications

(5 citation statements)

References 54 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As such, there is a mechanism by which soy isoflavones could theoretically modulate circulating cholesterol levels. However, isoflavone supplements taken by postmenopausal women for 12 weeks did not alter the expression of genes associated with the LDLR and scavenger receptor CD36, both of which are important in regulating plasma LDL-C concentrations [105]. Further, no significant changes in body fat and visceral adipose tissue were detected; in fact, a potentially deleterious significant increase in LDL-C was observed [105].…”

Section: Interventional Studies Involving Soymentioning

confidence: 99%

“…However, isoflavone supplements taken by postmenopausal women for 12 weeks did not alter the expression of genes associated with the LDLR and scavenger receptor CD36, both of which are important in regulating plasma LDL-C concentrations [105]. Further, no significant changes in body fat and visceral adipose tissue were detected; in fact, a potentially deleterious significant increase in LDL-C was observed [105]. This finding agrees with a meta-analysis which found that an average of 70 mg/day purified isoflavone aglycone extracts (27–132 mg/day), consumed independently of soy protein, did not significantly lower total or LDL-C in normocholesterolemic menopausal women [18].…”

Section: Interventional Studies Involving Soymentioning

confidence: 99%

See 1 more Smart Citation

Beyond the Cholesterol-Lowering Effect of Soy Protein: A Review of the Effects of Dietary Soy and Its Constituents on Risk Factors for Cardiovascular Disease

et al. 2017

View full text Add to dashboard Cite

The hypocholesterolemic effect of soy is well-documented and this has led to the regulatory approval of a health claim relating soy protein to a reduced risk of cardiovascular disease (CVD). However, soybeans contain additional components, such as isoflavones, lecithins, saponins and fiber that may improve cardiovascular health through independent mechanisms. This review summarizes the evidence on the cardiovascular benefits of non-protein soy components in relation to known CVD risk factors such as hypertension, hyperglycemia, inflammation, and obesity beyond cholesterol lowering. Overall, the available evidence suggests non-protein soy constituents improve markers of cardiovascular health; however, additional carefully designed studies are required to independently elucidate these effects. Further, work is also needed to clarify the role of isoflavone-metabolizing phenotype and gut microbiota composition on biological effect.

show abstract

Section: Interventional Studies Involving Soymentioning

confidence: 99%

Section: Interventional Studies Involving Soymentioning

confidence: 99%

Beyond the Cholesterol-Lowering Effect of Soy Protein: A Review of the Effects of Dietary Soy and Its Constituents on Risk Factors for Cardiovascular Disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…1, after full text assessment, 69 studies were excluded due to inappropriate study design, inappropriate population/exposure studies, or gender specific estimates missing. The remaining 23 RCTs [15][16][17][18][19][20][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43] were included in the review and meta-analysis. In total 1880 postmenopausal women (1130 in intervention arm and 750 in placebo arm) were included in the meta-analysis of 23 RCTs.…”

Section: Characteristics Of Included Rctsmentioning

confidence: 99%

Phytoestrogen supplementation and body composition in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials

et al. 2018

View full text Add to dashboard Cite

Phytoestrogen-based medications are commonly used by menopausal women, and especially by obese postmenopausal women, to relieve menopausal symptoms. Substitution of animal with soy protein is often used in weight loss regimens, yet the effect of phytoestrogens, the main constituent of soy foods, on body composition is not completely understood. We conducted a systematic review and meta-analysis to investigate the associations between phytoestrogen supplementation and body weight and the main parameters of body composition in postmenopausal women. A literature search was done using 5 electronic databases from inception to April 2018. Randomized controlled trials (RCTs) with postmenopausal women comparing phytoestrogen supplementation followed by usual diet and placebo were included in the present meta-analysis. From 5932 references, we identified 23 RCTs that met our inclusion criteria, with a total of 1880 postmenopausal women. No association was observed between phytoestrogen supplementation and body weight, body mass index, waist and hip circumference, total fat mass or percentage of body fat. However, the use of phytoestrogens supplementation was associated with a slight decrease in waist-hip ratio; the pooled mean difference was -0.01 cm (95%CI: -0.01 to -0.006). In subgroup analysis, we found a modest decrease in body weight with phytoestrogens supplementation compared with placebo in healthy postmenopausal women [pooled mean difference of changes -0.28 kg (95%CI: -0.52 to -0.04)] and in RCTs with a median number of participants of 66 or less [pooled mean difference of changes -0.49 kg (95%CI: -0.87 to -0.11)]. In contrast, phytoestrogen supplementation was associated with increased body weight in postmenopausal women with preexisting metabolic disorders (prediabetes, type 2 diabetes, prehypertension and hyperlipidemia) [pooled mean difference of changes: 0.78 kg (95%CI: 0.53-1.03)]. In addition, there were some indications that some types of phytoestrogens, such as daidzein, but not soy products or isoflavone mix, could lead to modest adverse changes in body composition in menopausal women. Therefore, future studies should investigate the potential adverse effects of phytoestrogen supplementation on body composition among postmenopausal women.

show abstract

“…The double-blind, placebo-controlled, randomized trial in parallel design with 179 postmenopausal women has been described previously [ 21 ]. The present study refers to a subgroup of women ( n = 60) who received for 12 weeks a commercially available, analytically well-characterized soy IF extract (for details, see [ 21 ], Supplementary Material Table S1 ) in capsule form for 12 weeks. Daily intake was 117.4 mg IF (genistein 49.7%; daidzein 41.4%; glycitein 9.0%).…”

Section: Methodsmentioning

confidence: 99%

Microbial Metabolism of the Soy Isoflavones Daidzein and Genistein in Postmenopausal Women: Human Intervention Study Reveals New Metabotypes

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background: Soy isoflavones belong to the group of phytoestrogens and are associated with beneficial health effects but are also discussed to have adverse effects. Isoflavones are intensively metabolized by the gut microbiota leading to metabolites with altered estrogenic potency. The population is classified into different isoflavone metabotypes based on individual metabolite profiles. So far, this classification was based on the capacity to metabolize daidzein and did not reflect genistein metabolism. We investigated the microbial metabolite profile of isoflavones considering daidzein and genistein. Methods: Isoflavones and metabolites were quantified in the urine of postmenopausal women receiving a soy isoflavone extract for 12 weeks. Based on these data, women were clustered in different isoflavone metabotypes. Further, the estrogenic potency of these metabotypes was estimated. Results: Based on the excreted urinary amounts of isoflavones and metabolites, the metabolite profiles could be calculated, resulting in 5 metabotypes applying a hierarchical cluster analysis. The metabotypes differed in part strongly regarding their metabolite profile and their estimated estrogenic potency.

show abstract

Isoflavone supplementation in postmenopausal women does not affect leukocyte LDL receptor and scavenger receptor CD36 expression: A double‐blind, randomized, placebo‐controlled trial

Abstract: Isoflavone supplementation for 12 weeks did not change LDLR and CD36 expression on leukocytes of PMW and did not affect body fat content and visceral adipose tissue (VAT), but slightly increased serum LDL-chol.

Cited by 9 publications

References 54 publications

Beyond the Cholesterol-Lowering Effect of Soy Protein: A Review of the Effects of Dietary Soy and Its Constituents on Risk Factors for Cardiovascular Disease

Beyond the Cholesterol-Lowering Effect of Soy Protein: A Review of the Effects of Dietary Soy and Its Constituents on Risk Factors for Cardiovascular Disease

Phytoestrogen supplementation and body composition in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials

Microbial Metabolism of the Soy Isoflavones Daidzein and Genistein in Postmenopausal Women: Human Intervention Study Reveals New Metabotypes

Contact Info

Product

Resources

About